Rationale and design of the RESTORE trial: A multicenter, randomized, double-blinded, parallel-group, placebo-controlled trial to evaluate the effect of Shenfu injection on myocardial injury in STEMI patients after primary PCI.
Xiao WangRuifeng GuoYingying GuoQian GuoYan YanWei GongWen ZhengHui WangLei XuHui AiBin QueXiaoyan YanXinliang MaShaoping NiePublished in: American heart journal (2023)
The RESTORE trial is sufficiently powered to demonstrate the clinical effects of Shenfu injection on myocardial injury in STEMI patients undergoing PPCI in the contemporary era.
Keyphrases
- phase iii
- double blind
- phase ii
- percutaneous coronary intervention
- study protocol
- patients undergoing
- st elevation myocardial infarction
- clinical trial
- end stage renal disease
- st segment elevation myocardial infarction
- open label
- placebo controlled
- chronic kidney disease
- newly diagnosed
- ejection fraction
- coronary artery disease
- ultrasound guided
- acute myocardial infarction
- prognostic factors
- randomized controlled trial
- peritoneal dialysis
- heart failure
- antiplatelet therapy